**TASL 2021 Annual Meeting & The 1ST TASL-EASL Joint Symposium**

**Theme：New challenges of liver diseases in the next decade**

Date: December 18 (Sat.) and 19 (Sun.), 2021

Add: 11F, Room1101, Chang Yung-Fa Foundation International Convention Center 張榮發基金會1101會議室

December 18, Saturday

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topics | Speakers | Moderators |
| 12:50-13:00  | **Opening** | Prof. Chau-Ting Yeh葉昭廷 教授 Prof. Han-Chieh Lin林漢傑 教授  |
| 13:00-13:50 | **Young Investigator Presentation** |
| 13:00-13:10 | High dimensional analysis for immune system interacting with cancer cells | Dr. Shih-Yu Chen陳世淯 博士 | Prof. Chia-Ho Shih施嘉和 教授 |
| 13:10-13:20 | Virus-associated host environmental changes in HCC | Dr. Shu-Chi Wang王述綺 助理教授 |
| 13:20-13:30 | Roles of non-coding RNA in HCC | Dr. Yang-Hsiang Lin林暘翔 博士 |
| 13:30-13:40 | New strategy of using iPSC-derived hepatocytes for liver diseases | Dr. Tsai-Jung Wu吳采蓉 博士 | Prof. Jaw-Ching Wu吳肇卿 教授  |
| 13:40-13:50 | Frequent and later off-therapy clinical relapse in hepatitis B e antigen-negative patients with higher HBV surface antigen at end-of-treatment | Dr. Yen-Chun Liu劉彥君 醫師 |
| 13:50-14:10 | **The history of TASL** | Prof. Yun-Fan Liaw廖運範 院士 | Prof. Chau-Ting Yeh葉昭廷 教授  |
| 14:10-14:50 | **The interplay between fatty liver and various chronic liver diseases**  |
| 14:10-14:30 | Fatty liver and viral hepatitis | Dr. Yi-Cheng Chen陳益程 副教授 | Prof. Sien-Sing Yang楊賢馨 教授 |
| 14:30-14:50 | Fatty liver and autoimmune liver disease | Prof. Atsushi Tanaka Japan | Prof. Huey-Ling Chen陳慧玲 教授 |
| 14:50-15:00 | **Coffee break** |

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topics | Speakers | Moderators |
| 15:00-17:15 | **1st TASL-EASL Joint Symposium****Metabolic dysfunction-** **associated fatty liver disease**  |
| 15:00-15:05 | **Opening** | Prof. Han-Chieh Lin林漢傑教授 |
| 15:05-15:25 | Diagnosis of lean NAFLD in Asia in the era of MAFLD | Prof. Chun-Jen Liu劉俊人 教授  | Prof. Han-Chieh Lin林漢傑 教授  |
| 15:25-15:45 | Immunologic approaches in the treatment of NAFLD-associated organ dysfunction: molecular aspects | Prof. Ying-Ying Yang楊盈盈 教授  |
| 15:45-16:05 | Non-invasive identification of patients with steatohepatitis with significant activity and fibrosis | Prof. Elisabetta BugianesiItaly | Prof. Jee-Fu Huang黃志富 教授   |
| 16:05-16:25 | Cardiovascular disease and MAFLD: current concepts and future challenges  | Prof. Vlad RatziuFrance |
| 16:25-16:55 | The current and future treatment of MAFLD | Prof. Philip NewsomeUK | Prof. Jia-Horng Kao高嘉宏 教授 |
| 16:55-17:10 | Panel Discussion | All |
| 17:10-17:15 | Closing | Prof. Jia-Horng Kao高嘉宏教授  |
| 17:15-18:00 | Satellite symposium I  | Room 1101 | Gilead (HBV) |
| 17:15-18:00 | Satellite symposium II | Room 1001 | BMS |
| 17:15-18:00 | Satellite symposium III | Room 1007 | EUROIMMUN |
| 18:00-18:45 | Satellite symposium IV | Room 1101 | Gilead (HCV) |
| 18:00-18:45 | Satellite symposium V | Room 1001 | Abbvie |
| 18:00-18:45 | Satellite symposium VI | Room 1002 | Sysmex |
| 18:00-18:45 | Satellite symposium VII | Room 1007 | PHIHPS |
| 19:10- | Gala Dinner (For Registered TASL Members and invited Guests) 台北晶華酒店4F萬象廳 |

**TASL 2021 Annual Meeting & The 1ST TASL-EASL Joint Symposium**

**Theme：New challenges of liver diseases in the next decade**

Date: December 18 (Sat.) and 19 (Sun.), 2021

Add: 11F, Room1101, Chang Yung-Fa Foundation International Convention Center 張榮發基金會1101會議室

December 19, Sun

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topics | Speakers | Moderators |
| 09:00-10:40  | **New challenges in chronic hepatitis B therapy** |
| 09:00-09:20 | How far should HBV treatment indications be expanded? | Prof. Anna SF LokUSA | Prof. Chien-Jen Chen陳建仁 院士 |
| 09:20-09:40 | Finite NUC therapy: from an “option” to a “firm recommendation” | Prof. Yun-Fan Liaw廖運範 院士 | Prof. Rong-Nan Chien簡榮南 教授 |
| 09:40-10:00 | Targeting the HBV core proteinphosphorylation for antiviral development | Prof. Shiou-Hwei Yeh葉秀慧 教授 | Prof. Sen-Yung Hsieh謝森永 教授 |
| 10:00-10:20 | New horizon for HBV cure – new drugs on pipeline | Prof. Hung-Chih Yang楊宏志 教授 | Prof. Tsung-Hui Hu胡琮輝 教授 |
| 10:20-10:40 | Biomarkers utility in finite therapy | Prof. Chien-Hung Chen陳建宏 教授 | Prof. Jia-Horng Kao高嘉宏 教授 |
| 10:40-10:50 | **Coffee break** |
| 10:50-11:50 | **Portal hypertension and complications of liver cirrhosis**  |
| 10:50-11:10 | Management of Portal Hypertension: Baveno Updates. | Prof. Guadalupe Garcia-Tsao USA | Prof. Gin-Ho Lo羅錦河 教授 |
| 11:10-11:30 | Is regression of liver cirrhosis definitely accompanied by amelioration of portal hypertension? | Prof. Hui-Chun-Huang黃惠君 教授 | Prof.Ting-Tsung Chang張定宗 教授 |
| 11:30-11:50 | Relative adrenal insufficiency in liver cirrhosis. | Prof. Ming-Hung Tsai蔡銘鴻 教授 | Prof. Fa-Yauh Lee李發耀 教授 |
| 11:50-12:30 | **Chairman lecture**Genomic marker guided anticancer treatment for HCC - a preliminary scheme | Prof. Chau-Ting Yeh葉昭廷 教授 | Prof. Yun-Fan Liaw廖運範 院士 |
| 12:30-13:15 | Satellite symposium I | Room 1101 | Bayer |
| 12:30-13:15 | Satellite symposium II | Room 1001 | MSD/ Eisai |
| 12:30-13:15 | Satellite symposium III | Room 1002 | Grifols |
| 13:15-14:00 | Satellite symposium IV | Room 1101 | Roche |
| 13:15-14:00 | Satellite symposium V | Room 1001 | MSD/ Eisai |

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topics | Speakers | Moderators |
| 14:00-15:40 | **Update and perspective on HCC therapies** |
| 14:00-14:20 | Overview of systemic therapy in unresectable HCC | Prof. Ann Lii Cheng鄭安理 教授 | Prof. Chau-Ting Yeh葉昭廷 教授 |
| 14:20-14:40 | ICI-based combination therapy in unresectable HCC: first line setting | Prof. Yi-Hsiang Huang黃怡翔 教授 | Prof. Chun-Yen Lin林俊彥 教授 |
| 14:40-15:00 | Second line or further therapy in unresectable HCC | Prof. Masatoshi KudoJapan | Prof. Shi-Ming Lin林錫銘 教授 |
| 15:00-15:20 | Immune adverse events during ICI-based therapy for HCC | Prof. Stephen ChanHong Kong | Prof. Cheng-Yuan Peng彭成元 教授 |
| 15:20-15:40 | Evolving Strategies in LDLT for HCC: 2021 Update | Prof. Chao-Long Chen陳肇隆 教授 | Prof. Pei-Jer Chen陳培哲 院士 |
| 15:40-15:50 | **Coffee break** |
| 15:50-17:10 | **The future issues on HCV infection** |
| 15:50-16:10 | Searching for HCV infection in rural area: any cost-effective strategy? | Prof. Sheng-Nan Lu盧勝男 教授 | Prof. Hwai- I Yang楊懷壹 教授 |
| 16:10-16:30 | Hepatitis C-associated cardiometabolic complications: to reverse or not to reverse after SVR? | Prof. Francesco Negro Switzerland | Prof. Wan-Long Chuang莊萬龍 教授 |
| 16:30-16:50 | DAA treatment in hepatocellular carcinoma: to treat or not to treat? | Prof. Chia-Yen Dai戴嘉言 教授 | Prof. Chao-Hung Hung洪肇宏 教授 |
| 16:50-17:10 | Hepatitis C-associated mixed cryoglobulinemia: the ignored majority in Taiwan | Prof. Ming-Ling Chang張明鈴 教授 | Prof. Ming-Lung Yu余明隆 教授 |
| 17:10-17:20 | Research award | Prof. Chia-Ming Chu朱嘉明 教授 |
| 17:20-17:30 | Closing remarks | Prof. Han-Chieh Lin林漢傑 教授 |